SGLT-2 inhibitors beyond diabetes: a new frontier in cancer treatment

Area of Science:

• Oncology
• Pharmacology
• Metabolic Diseases

Background:

• Sodium-glucose co-transporter 2 (SGLT-2) is present in various cancer cell lines.
• Cancer cells often exhibit increased glucose dependency for proliferation.
• SGLT-2 inhibitors are established antidiabetic medications with a known safety profile.

Purpose of the Study:

• To explore the anti-cancer potential of SGLT-2 inhibitors.
• To investigate the mechanisms underlying the anti-cancer effects of SGLT-2 inhibitors.
• To evaluate SGLT-2 inhibitors as novel therapeutic agents in oncology.

Main Methods:

• In vitro and in vivo studies were conducted across multiple cancer types.
• The antiproliferative effects of SGLT-2 inhibitors were assessed.
• Intracellular and extracellular signaling pathways influenced by SGLT-2 inhibitors were analyzed.

Main Results:

• SGLT-2 inhibitors demonstrated significant antiproliferative effects in various cancer models.
• These effects were observed through mechanisms independent of SGLT-2 activity.
• Key pathways regulated include those involving microRNAs, AMPK, ERK, DNA/RNA metabolism, ATP homeostasis, and mitochondrial function.

Conclusions:

• SGLT-2 inhibitors represent a promising therapeutic strategy for cancer treatment.
• Their anti-cancer efficacy is mediated by diverse signaling pathways, offering broad applicability.
• Further clinical investigation in oncology is warranted to leverage these findings.